Published in final edited form as:

Tetrahedron Lett. 2017 August 16; 58(33): 3230–3233. doi:10.1016/j.tetlet.2017.07.010.

An enantioselective enzymatic desymmetrization route to hexahydro-4*H*-furopyranol, a high-affinity ligand for HIV-1 protease inhibitors

Arun K. Ghosh* and Anindya Sarkar

Department of Chemistry and Department of Medicinal Chemistry, Purdue University, 560 Oval Drive, West Lafayette, Indiana 479 07, United States

Abstract

An enantioselective synthesis of (3*aS*,4*S*,7*aR*)-hexahydro-4*H*-furo[2,3-*b*]pyran-4-ol, a high-affinity nonpeptide ligand for a variety of potent HIV-1 protease inhibitors is described. The key steps involved a highly enantioselective enzymatic desymmetrization of *meso*-diacetate, an efficient transacetalization, and a highly diastereoselective reduction of a ketone. This route is amenable to large-scale synthesis using readily available starting materials.

Graphical abstract

Keywords

Enzymatic hydrolysis; Enantioselective; Desymmetrization; HIV-1 Protease Inhibitors; Ligand

The development of combined antiretroviral therapy (cART) with HIV-1 protease inhibitors (PIs) dramatically transformed HIV/AIDS from a terminal disease to a chronic ailment.^{1,2} This treatment regimen improved life expectancies of those patients with access to cART.^{3,4} Despite this remarkable progress, there are numerous drug-related complications. Perhaps, the most concerning is the rapid emergence of multidrug-resistant HIV-1 variants which severely limit the current and future management of HIV/AIDS.^{5–7} In our continuing efforts in developing novel protease inhibitors (PIs) with broad-spectrum activity against multidrug-

*Corresponding author. akghosh@purdue.edu.

Supplementary Data

Supplementary data associated with this article can be found in the online version.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

resistant HIV-1 variants, we reported inhibitors containing fused *bis*-tetrahydrofuran and tetrahydropyranyl tetrahydrofuran represented in PIs **1–4** (Figure 1).^{8–10} Among these PIs, darunavir (**1**) is an FDA approved drug and it is used as a front-line therapy for HIV/AIDS patients.^{11–12} Darunavir and its methoxy derivative (**1** and **2**) contain (3*R*,3*a**S*,6*a**R*)-*bis*-tetrahydrofuranyl (*bis*-THF) urethane as the P2 ligand.^{8,9} Darunavir's exceptional antiretroviral activity against multidrug-resistant clinical isolates and high genetic barrier to resistance is attributed to the presence of the *bis*-THF ligand.^{13–15} Darunavir exhibited dual mechanism of action by blocking HIV-1 protease enzymatic activity as well as by inhibiting dimerization of protease monomers.¹⁶ Structurally, darunavir was designed to make extensive interactions in the active site of HIV-1 protease, particularly with the backbone atoms from S2 and S2' subsites.^{9,17}

In an effort to further optimize the *bis*-THF structural template of darunavir, we explored modifications that would enhance the 'backbone binding' as well as improve hydrophobic interactions in the protease active site.^{10,17} Interestingly, the ring-fusion, stereochemistry, and position of urethane are critical to inhibitor potency. Inhibitor **3**, with a (3*R*,3*a**S*,7*a**R*)-hexahydro-4*H*-furo[2,3-*b*]pyran-3-ol, is significantly less potent than inhibitors **1** and **2**.^{8,11} However, incorporation of isomeric (3*a**S*,4*S*,7*a**R*)-hexahydro-4*H*-furo[2,3-*b*]pyran-4-ol (*TP*-THF) resulted in inhibitor **4** which showed excellent protease inhibitory activity ($K_i = 2.7$ pM) and improved antiviral activity in MT cells ($IC_{50} = 0.5$ nM) compared to inhibitor **2** ($K_i = 14$ pM, $IC_{50} = 2.3$ nM).¹⁸ Furthermore, inhibitor **4** showed retention of antiviral activity against a panel of multidrug-resistant clinical HIV-1 strains with IC_{50} values in the nanomolar range and is superior to other approved PIs and comparable to darunavir.^{18,19} The X-ray structural analysis revealed that the hydrogen bonding interactions of both P2 ligand oxygens are significantly stronger than the *bis*-THF ligand in darunavir or inhibitor **2** (Figure 2).²⁰ This may be due to the fact that the *TP*-THF ligand of inhibitor **4** has higher affinity for the active site of HIV-1 protease. For the synthesis of *TP*-THF ligand, we previously converted optically active bicyclic lactone **5** to (3*a**S*,4*S*,7*a**R*)-hexahydro-4*H*-furo[2,3-*b*]pyran-4-ol **6**.¹⁸ Lactone **5** was obtained from cyclopentene diacetate as the key starting material.²¹ To expand the use of the *TP*-THF ligand, we have now explored an alternative synthetic route using readily available and inexpensive starting materials. Herein, we report a convenient enantioselective synthesis of (3*a**S*,4*S*,7*a**R*)-hexahydro-4*H*-furo[2,3-*b*]pyran-4-ol using an efficient enzymatic desymmetrization of *meso*-diacetate as the key reaction.

The synthetic strategy for optically active hexahydro-4*H*-furopyranol **6** is shown in Scheme 1. The 6,5-fused ring structure would be obtained through a transacetalization reaction on diol **7**. Optically active diol **7** can be derived from the oxidative cleavage of cyclohexene derivative **8**, which could be obtained from optically active alcohol **9**. Alcohol **9** can be prepared from commercially available *meso*-diacetate **10** by an enzymatic desymmetrization process.

The synthesis and enzymatic desymmetrization are shown in Scheme 2. *Cis-meso*-diacetate **10** was prepared in multigram quantity from commercially available, inexpensive, 1,2,3,6-tetrahydrophthalic anhydride **11** by LAH reduction followed by acetylation as reported in the literature.²² Initially, we carried out enzymatic desymmetrization of *meso*-diacetate **10**

by treatment with Porcine Pancreatic Lipase (PPL, 5 % w/w, Sigma, type II, crude)²³ in 0.1 M phosphate buffer (pH 7) over 24 h to afford optically active monoacetate **9** in >95% *ee*. During this enzymatic reaction, aqueous 1 N NaOH was added dropwise to neutralize the acetic acid formed during the reaction.^{22,24} However, when the reaction was performed on a gram-scale, inconsistent yields and varying degree of optical purity were observed. This is presumably due to non-enzymatic hydrolysis of the monoacetate **9** and diacetate **10** promoted by aqueous 1 N NaOH in the reaction. In a modified protocol, we subsequently used aqueous 1 N NaHCO₃ instead of 1 N aqueous NaOH to neutralize the liberated acetic acid. This condition afforded monoacetate **9** in 84% yield and high enantiomeric purity (99% *ee*). The reaction yield and optical purity were reproducible even on a 60 g scale reaction.²⁵

For the synthesis of the ligand alcohol **6**, monoacetate **9** was oxidized using Swern oxidation to provide the corresponding aldehyde in 94% yield. Protection of the aldehyde with ethylene glycol in presence of a catalytic amount of camphorsulfonic acid (CSA) gave the desired acetal in poor yield (11%). We screened a number of other protecting groups, acid catalysts and solvents and the results are shown in Table 1. The use of *bis*(trimethylsilyloxy) ethane (1.3 equiv) in the presence of TMSOTf afforded 30% yield of the corresponding 1,3-dioxolane derivative (entry 2). Reaction of aldehyde with trimethyl orthoformate (30 equiv) in methanol at 23 °C in the presence of a catalytic amount of PPTS afforded dimethyl acetal **12** in 27% yield (entry 3). When the reaction was carried out in CH₂Cl₂ with 0.2 equivalent of PPTS, acetal yield improved to 76% (entry 4). The use of a catalytic amount of CSA (0.2 equivalent) and in the presence of anhydrous MgSO₄ in CH₂Cl₂ at 23 °C for 12 h provided acetal **12** in 89% yield (entry 5).

Oxidative cleavage of the olefin by ozonolysis in the presence of pyridine as the organocatalyst²⁶ in CH₂Cl₂ at –78 °C, followed by reduction of the resulting crude dialdehyde with sodium borohydride at 0 °C to 23 °C afforded diol **13**. Treatment of diol **13** with a catalytic amount (30 mol %) of CSA in CH₂Cl₂ at 23 °C for 2 h furnished bicyclic acetal **14** via lactol intermediate **13A** in 56% yield over 3 steps.

Bicyclic acetal **14** was converted to hexahydro-4*H*-furopyranol **6** as shown in Scheme 3. Removal of the acetate was carried out by treatment of **14** with potassium carbonate in methanol at 23 °C for 1 h to afford alcohol **15** in 98% yield. Alcohol **15** was subjected to an elimination reaction using a protocol developed by Grieco and co-workers.²⁷ Alcohol **15** was treated with *o*-nitrophenylselenonitrile and *n*-tributylphosphine in THF at 23 °C for 45 min to provide the corresponding selenide derivative. Oxidation of the resulting selenide with *m*-CPBA in CH₂Cl₂ at 23 °C for 10 min resulted in elimination of the corresponding selenoxide to afford olefin **16** in 71% yield over 2-steps. We also explored alternative pathways to convert alcohol **15** to olefin **16**. Tosylation of alcohol **15** with tosyl chloride in the presence of triethylamine and a catalytic amount of DMAP at 23 °C for 2 h provided tosylate derivative **17** in 70% yield. However, elimination of the tosylate with sodium iodide and DBU in 1,2-dimethoxyethane at 90 °C for 3 h furnished olefin **16** in low yield (31%).²⁸ Further attempted elimination of the tosylate with potassium *tert*-butoxide in DMSO provided only trace amount of elimination product and mostly resulted in the decomposition of the tosylate. We carried out oxidative cleavage of exocyclic olefin **16** by ozonolysis in

CH₂Cl₂ at –78 °C to furnish the corresponding ketone in 88% yield. Reduction of the resulting ketone with sodium borohydride in ethanol at 23 °C for 15 min provided alcohol **6** ([α]_D²³ –31.1 (*c* 1, CHCl₃) in 90% yield.

Optically active ligand alcohol **6** was converted to HIV-1 protease inhibitor **20** as shown in Scheme 4. Alcohol **6** was converted to the activated mixed carbonate **18** by treatment with disuccinimidyl carbonate in the presence of Et₃N in CH₂Cl₂ at 23 °C for 18 h.²⁹ Reaction of carbonate **18** with the known (hydroxyethyl)sulfonamide isostere³⁰ **19** in the presence of diisopropylethylamine at 23 °C for 1 h afforded inhibitor **20** in 85% yield over 2 steps. Inhibitor **20** was evaluated in an enzyme inhibitory assay following a protocol described by Toth and Marshall.³¹ As reported previously, inhibitor **20** showed a K_i value of 10 pM, comparable to that of Darunavir (16 pM).¹⁸

In conclusion, we have carried out an optically active synthesis of the P₂ ligand, (3a*S*,4*S*,7a*R*)-hexahydro-4*H*-furo[2,3-*b*]pyran-4-ol. This nonpeptide ligand is a high affinity P₂ ligand for a variety of exceptionally potent HIV-1 protease inhibitors. The key step involved the synthesis of optically active ((1*R*,6*S*)-6-(hydroxymethyl)cyclohex-3-en-1-yl)methyl acetate **9** by a very efficient enzymatic desymmetrization of *meso*-diacetate **10** using commercially available and inexpensive porcine pancreatic lipase. The enzymatic desymmetrization was carried out in large scale providing acetate **9** in high optical purity (up to 99% ee). Optically active alcohol **9** was efficiently converted to (3a*S*,4*S*,7a*R*)-hexahydro-4*H*-furo[2,3-*b*]pyran-4-ol. This ligand alcohol was then converted to HIV-1 protease inhibitor **20**. Further studies, particularly scopes and application are in progress in our laboratory.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support by the National Institutes of Health is gratefully acknowledged.

References and notes

1. Fauci AS, Marston HD. N Engl J Med. 2015; 373:2197–2199. [PubMed: 26624554]
2. Tan IL, McArthur JC. CNS Drugs. 2012; 26:123–134. [PubMed: 22201342]
3. Montaner JSG, Lima VD, Barrios R, Yip B, Wood E, Kerr T, Shannon K, Harrigan PR, Hogg RS, Daly P, Kendall P. Lancet. 2010; 376:532–539. [PubMed: 20638713]
4. Lohse N, Hansen AB, Gerstoft J, Obel N. J Antimicrob Chemother. 2007; 60:461–463. [PubMed: 17609196]
5. De Clercq E. Int J Antimicrob Agents. 2009;307–320. [PubMed: 19108994]
6. Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, Gifford R, Nielsen C, Pedersen C, Balotta C, Rezza G, Ortiz M, de Mendoza C, Kucherer C, Poggensee G, Gill J, Porter K. AIDS. 2006; 20:21–28. [PubMed: 16327315]
7. Esté JA, Cihlar T. Antiviral Res. 2010; 85:25–33. [PubMed: 20018390]
8. Ghosh AK, Sridhar PR, Kumaragurubaran N, Koh Y, Weber IT, Mitsuya H. Chem Med Chem. 2006; 1:939–950. [PubMed: 16927344]

9. Ghosh AK, Chapsal BD, Weber IT, Mitsuya H. *Acc Chem Res.* 2008; 41:78–86. [PubMed: 17722874]
10. Ghosh AK, Osswald HL, Prato G. *J Med Chem.* 2016; 59:5172–5208. [PubMed: 26799988]
11. Ghosh AK, Kincaid JF, Cho W, Walters DE, Krishnan K, Hussain KA, Koo Y, Cho H, Rudall C, Holland L, Buthod J. *Bioorg Med Chem Lett.* 1998; 8:687–690. [PubMed: 9871583]
12. Ghosh AK, Dawson ZL, Mitsuya H. *Bioorg Med Chem.* 2007; 15:7576–7580. [PubMed: 17900913]
13. Ghosh, AK., Chapsal, BD. Design of the anti-HIV-1 protease inhibitor darunavir in *Introduction to Biological and Small Molecule Drug Research and Development: Theory and case studies.* Ganellin, CR, Jefferis, R., Roberts, S., editors. Elsevier; London: 2013. p. 355–384.
14. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. *Antimicrob Agents Chemother.* 2003; 47:3123–3129. [PubMed: 14506019]
15. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA. *J Virol.* 2004; 78:12012–12021. [PubMed: 15479840]
16. Koh Y, Matsumi S, Das D, Amano M, Davis DA, Leschenko S, Baldrige A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H. *J Biol Chem.* 2007; 282:28709–28720. [PubMed: 17635930]
17. Ghosh AK, Anderson DD, Weber IT, Mitsuya H. *Angew Chem, Int Ed.* 2012; 51:1778–1802.
18. Ghosh AK, Chapsal BD, Baldrige A, Steffy MP, Walters DE, Koh Y, Amano M, Mitsuya H. *J Med Chem.* 2011; 54:622–634. [PubMed: 21194227]
19. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune M-P, Schiffer CA. *J Virol.* 2004; 78:12012–12021. [PubMed: 15479840]
20. Kovalevsky AY, Liu F, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT. *J Mol Biol.* 2006; 363:161–173. [PubMed: 16962136]
21. Laumen K, Schneider MP. *J Chem Soc, Chem Commun.* 1986:1298–1299.
22. Von Langen DJ, Tolman RL. *Tetrahedron: Asymmetry.* 1997; 8:677–681.
23. PPL was purchased from Sigma Aldrich Co., St. Louis, MO.
24. Schmidt JP, Beltra'n-Rodil S, Cox RJ, McAllister GD, Reid M, Taylor RJK. *Org Lett.* 2007; 9:4041–4044. [PubMed: 17764195]
25. Ghosh AK, Sarkar A. *Eur J Org Chem.* 2016:6001–6009.
26. Willand-Charnley R, Fisher TJ, Johnson BM, Dussault PH. *Org Lett.* 2012; 14:2242–2245. [PubMed: 22512349]
27. Grieco PA, Gilman S, Nishizawa M. *J Org Chem.* 1976; 41:1485–1486.
28. Phukan P, Bauer M, Maier ME. *Synthesis.* 2003:1324–1328.
29. Ghosh AK, Duong TT, McKee SP. *Tetrahedron Letters.* 1992; 33:2781–2784.
30. Ghosh AK, Sridhar PR, Leshchenko S, Hussain AK, Li J, Kovalevsky AY, Walters DE, Wedekind JE, Grum-Tokars V, Das D, Koh Y, Maeda K, Gatanaga H, Weber IT, Mitsuya H. *J Med Chem.* 2006; 49:5252–5261. [PubMed: 16913714]
31. Toth MV, Marshall GR. *Int J Pept Protein Res.* 1990; 36:544–550. [PubMed: 2090647]

Figure 1.
Structures of protease inhibitors 1-4

Figure 2.
The key hydrogen bonding interactions of hexahydro-4 *H*-fuopyranol ligand of inhibitor **4** with Asp29 and Asp30.

Scheme 1.

An enzymatic desymmetrization strategy for hexahydro-4*H*-fuopyranol

Scheme 2.
Synthesis of bicyclic acetal **14**

Scheme 3.
Synthesis of ligand alcohol **6**

Scheme 4.
Synthesis of HIV-1 protease inhibitor **20**

Table 1Optimization of acetal protection for compound **12**

Entry	Reagent	Acid (equiv)	Temp (°C)	Time (h)	Yield ^a (%)
1 ^a	Ethylene glycol	CSA (0.2)	80	0.5	11
2 ^b	TMSO(CH ₂) ₂ -OTMS	TMSOTf (1.3)	-78	2	30
3 ^c	HC(OMe) ₃	PPTS (0.3)	23	24	27
4 ^b	HC(OMe) ₃	PPTS (0.2)	23	72	76 ^d
5 ^b	HC(OMe) ₃	CSA (0.2)	23	12	89 ^d

^a Solvent: benzene;^b solvent: CH₂Cl₂;^c solvent MeOH;^d anhydrous MgSO₄ was used.